Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04793295 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
A Phase 1 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT04793295 is a Phase 1 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 112 participants.
The verdict
NCT04793295, a Phase 1 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
Study is to investigate drug levels in the blood after taking single or multiple doses of the study drug, MT-7117, in healthy adults when taken together with another drug. This study will also look at the safety and the body's ability to tolerate MT-7117
Interventions
- DRUG MT-7117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-03-23 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04793295
The ClinicalTrials.gov registry entry for NCT04793295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-7117 is the first listed.
NCT04793295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04793295 about?
NCT04793295 is a clinical study titled "Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects". Study is to investigate drug levels in the blood after taking single or multiple doses of the study drug, MT-7117, in healthy adults when taken together with another drug. This study will also look at the safety and the body's ability to tolerate MT-7117
What is the current status of trial NCT04793295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2021-03-23. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT04793295?
The interventions under investigation include: MT-7117 (DRUG).
Who is sponsoring clinical trial NCT04793295?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.